

Miguel Munoz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3761963/miguel-munoz-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

1,950

citations

27

h-index

43

g-index

72

ext. papers

2,273

ext. citations

3.6

avg, IF

5.15

L-index

#	Paper	IF	Citations
66	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013 , 4, 502-30	3.3	131
65	Involvement of substance P and the NK-1 receptor in human pathology. <i>Amino Acids</i> , 2014 , 46, 1727-50	3.5	117
64	Involvement of substance P and the NK-1 receptor in cancer progression. <i>Peptides</i> , 2013 , 48, 1-9	3.8	92
63	The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. <i>Investigational New Drugs</i> , 2010 , 28, 187-93	4.3	88
62	The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. <i>Tumor Biology</i> , 2008 , 29, 245-54	2.9	80
61	The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. <i>Neuropeptides</i> , 2005 , 39, 427-32	3.3	77
60	Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. <i>Journal of Hepatology</i> , 2014 , 60, 985-94	13.4	72
59	NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEP-2. <i>Investigational New Drugs</i> , 2008 , 26, 111-8	4.3	69
58	The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. <i>Laboratory Investigation</i> , 2010 , 90, 1259-69	5.9	68
57	A new frontier in the treatment of cancer: NK-1 receptor antagonists. <i>Current Medicinal Chemistry</i> , 2010 , 17, 504-16	4.3	66
56	The NK-1 receptor: a new target in cancer therapy. <i>Current Drug Targets</i> , 2011 , 12, 909-21	3	62
55	The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. <i>Journal of Biosciences</i> , 2015 , 40, 441-63	2.3	60
54	Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. <i>Melanoma Research</i> , 2004 , 14, 183-8	3.3	57
53	Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 2567-70		51
52	The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. <i>Peptides</i> , 2012 , 38, 318-25	3.8	49
51	Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. <i>Investigative Ophthalmology and Visual Science</i> , 2007 , 48, 2775-81		49
50	The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. <i>International Journal of Oncology</i> , 2014 , 45, 1658-72	4.4	44

49	Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. <i>Histopathology</i> , 2009 , 54, 258-60	7.3	40
48	NK-1 receptor antagonists: a new paradigm in pharmacological therapy. <i>Current Medicinal Chemistry</i> , 2011 , 18, 1820-31	4.3	40
47	The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. <i>Scientific World Journal, The</i> , 2012 , 2012, 381434	2.2	39
46	A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. <i>Anticancer Research</i> , 2009 , 29, 2323-9	2.3	39
45	Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. <i>International Journal of Oncology</i> , 2014 , 44, 137-46	4.4	35
44	Safety of neurokinin-1 receptor antagonists. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 673-85	4.1	34
43	The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. <i>Investigational New Drugs</i> , 2012 , 30, 529-40	4.3	32
42	Cancer progression and substance P. <i>Histology and Histopathology</i> , 2014 , 29, 881-90	1.4	31
41	The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines. <i>Letters in Drug Design and Discovery</i> , 2006 , 3, 323-329	0.8	29
40	Neurokinin-1 receptor: a new promising target in the treatment of cancer. <i>Discovery Medicine</i> , 2010 , 10, 305-13	2.5	27
39	Involvement of substance P and the NK-1 receptor in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2321-34	5.6	26
38	Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 425-31	4.8	23
37	Primary leptomeningeal melanoma in a child. <i>Pediatric Neurology</i> , 2001 , 24, 390-2	2.9	20
36	Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach. <i>Saudi Journal of Gastroenterology</i> , 2016 , 22, 260-8	3	20
35	NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. <i>Expert Opinion on Therapeutic Patents</i> , 2012 , 22, 735-46	6.8	19
34	The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?. <i>Cancers</i> , 2020 , 12,	6.6	19
33	Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 601-3	4.4	17
32	Immunolocalization of NK-1 receptor and Substance P in human normal placenta. <i>Placenta</i> , 2010 , 31, 649-51	3.4	17

31	The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. <i>Cancers</i> , 2010 , 2, 611-23	6.6	16
30	Kluyvera meningitis in a newborn. <i>Pediatric Infectious Disease Journal</i> , 2007 , 26, 1070-1	3.4	16
29	NK-1 as a melanoma target. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 889-97	6.4	14
28	Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2019 , 11, 50-54	1.6	12
27	Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach. <i>Cancers</i> , 2015 , 7, 1215-32	6.6	11
26	The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile. <i>Peptides</i> , 2010 , 31, 1643-8	3.8	10
25	NK-1 receptor antagonists: a new generation of anticancer drugs. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012 , 12, 593-9	3.2	10
24	Seizures caused by chloral hydrate sedative doses. <i>Journal of Pediatrics</i> , 1997 , 131, 787-8	3.6	10
23	Primary idiopathic chylopericardium in a 2 month old successfully treated without surgery. <i>Journal of Pediatric Surgery</i> , 2000 , 35, 646-8	2.6	10
22	Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. <i>Investigational New Drugs</i> , 2019 , 37, 17-26	4.3	10
21	The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. <i>Pharmacological Reports</i> , 2017 , 69, 696-701	3.9	9
20	The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
19	Neurokinin-1 Receptor Antagonists against Hepatoblastoma. <i>Cancers</i> , 2019 , 11,	6.6	8
18	Neurokinin receptor antagonism: a patent review (2014-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020 , 30, 527-539	6.8	8
17	Immunolocalization of Substance P and NK-1 Receptor in ADIPOSE Stem Cells. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 4686-4696	4.7	7
16	Increased nuclear localization of substance P in human gastric tumor cells. <i>Acta Histochemica</i> , 2017 , 119, 337-342	2	7
15	Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose. <i>Acta Dermato-Venereologica</i> , 2019 , 99, 620-621	2.2	7
14	Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor. <i>Peptides</i> , 2014 , 55, 1-12	3.8	6

13	Immunolocalization of substance P and NK-1 receptor in Hofbauer cells in human normal placenta. <i>Microscopy Research and Technique</i> , 2013 , 76, 1310-3	2.8	6
12	The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. <i>European Journal of Histochemistry</i> , 2020 , 64,	2.1	4
11	Neurokinin-1 Receptor Antagonists as Anticancer Drugs. <i>Letters in Drug Design and Discovery</i> , 2019 , 16, 1110-1129	0.8	4
10	Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020 , 20, 408-417	3.2	3
9	Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019 , 19, 92-100	2.2	3
8	Immunolocalization of substance P and NK-1 receptor in vascular anomalies. <i>Archives of Dermatological Research</i> , 2017 , 309, 97-102	3.3	2
7	Prognostic Significance of Substance P/Neurokinin 1 Receptor and Its Association with Hormonal Receptors in Breast Carcinoma. <i>BioMed Research International</i> , 2021 , 2021, 5577820	3	2
6	Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy. <i>Letters in Drug Design and Discovery</i> , 2017 , 14,	0.8	2
5	Prognostic significance of Substance P/ Neurokinin 1 receptor and its association with hormonal receptors in breast carcinoma		1
4	Substance P 2018 , 571-578		1
3	The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.. <i>BioMed Research International</i> , 2022 , 2022, 6291504	3	0
2	Why use aprepitant only as a cough suppressant in lung cancer when at higher doses it could also exert an antitumor action?. <i>Archivos De Bronconeumologia</i> , 2022 ,	0.7	0
1	Resistance to a beta-lactam antibiotic appearing during therapy for enterobacter cloacae sepsis in a child. <i>Medical and Pediatric Oncology</i> , 2003 , 40, 62-3		